Adding to its putative prognostic value, EZH2 is also an actionable target, and several clinical trials evaluating the efficacy of anti-EZH2 drugs in refractory/relapsed DLBCL are currently ongoing [8]. The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.